FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.

The platinum-free combination significantly improved EFS, OS, and pathologic complete response rates compared with standard neoadjuvant gemcitabine/cisplatin.

FDA Drug Approvals and Regulatory Updates Drug Pharmacologic class Indication More information Cardiovascular Disease Tryngolza (olezarsen) Apolipoprotein ...

The share of US adults taking GLP-1 medications to lose weight has reached a record 11%, a new Medicare program that began July 1 could drive that figure higher still.

For men with lower urinary tract symptoms (LUTS) attributable to benign prostatic hyperplasia (BPH) who are continuous users of tamsulosin, about one-third have ...

Treatments for fibrodysplasia ossificans progressiva, gastroenteropancreatic neuroendocrine tumors, HIV, influenza, and multiple myeloma are under review.

Topline data from the phase 3 E-BEOND and C-BEOND trials show a significant reduction in monthly migraine days at 24 weeks, demonstrating efficacy across the full migraine spectrum.

Three in 10 young adults do not have a primary care doctor, according to the results of a survey released June 29 by The Ohio State University Wexner Medical Ce ...

Supported by WILLOW trial findings, the oral TLR 7/8 inhibitor demonstrated significant, dose-dependent reductions in skin disease activity for patients with lupus.

A new treatment is approved to reduce proteinuria in adults with primary immunoglobulin A nephropahty; a swimmer’s ear treatment and the thyroid hormone replacement therapy Amerithroid are now ...

Sibling-matched analysis showed no association between prenatal acetaminophen exposure with risks in offspring ...

The phase 3 CARDIO-TTRansform trial evaluated subcutaneous eplontersen vs placebo in 1432 adults with ATTR-CM.